Kernaussagen
Erreger. Als „CA-MRSA” werden Varianten von S. aureus bezeichnet, die eine erhöhte Antibiotikaresistenz (Beta-Laktame und andere) in Kombination mit besonderen Virulenzeigenschaften aufweisen. „CA” steht dabei für „community-associated” (wahlweise auch „adapted”, „acquired”), weil die Stämme im Unterschied zu bisherigen MRSA-Isolaten außerhalb medizinischer Einrichtungen bei Patienten ohne nosokomiale Risikofaktoren auftreten.
Krankheitsbilder. CA-MRSA verursachen typischerweise Haut-Weichteilinfektionen, die bei bis zu 30 % der Fälle multipel oder rezidivierend auftreten. Übertragungen auf Personen mit engem körperlichem Kontakt sind häufig. Selten kommt es zur Bildung von Abszessen in tiefen Kompartimenten oder schweren systemischen Erkrankungen mit hoher Letalität (Nekrotisierende Pneumonie, Nekrotisierende Fasziitis).
Diagnostik. Kultur, Resistenzbestimmung und Bestimmung des Virulenzmarkers „Panton-Valentine Leukozidin” sollten durchgeführt werden, wenn der klinische Verlauf bzw. anamnestische Angaben (Häufung von Erkrankungsfällen, Reiseanamnese) auf CA-MRSA hinweisen.
Therapie. Die primäre Therapie folgt allgemeinen Grundsätzen. Die Antibiotikaresistenz sollte beachtet werden. Zur Verhütung von rezidivierenden Infektionen bzw. schwerer Komplikationen sollte eine Sanierung des Trägerstatus durchgeführt werden.
Prävention. In medizinischen Einrichtungen, insbesondere im Bereich der Primärversorgung, sollten die bestehenden Hygienerichtlinien optimal umgesetzt werden. Infizierte oder kolonisierte Patienten sollten saniert werden. Für medizinisches Personal wird die Impfung gegen Influenza A empfohlen.
Epidemiologie. Weltweit wird in den letzten Jahren eine starke Zunahme von CA-MRSA bei Patienten ohne Risikofaktoren und ohne Kontakt zu medizinischen Einrichtungen beobachtet. In den USA sind CA-MRSA der häufigste Verursacher von ambulant erworbenen Haut-/Weichteilinfektionen geworden. In Deutschland sind CA-MRSA noch selten.
Ausblick. Wegen der Bedeutung von CA-MRSA für die allgemeine Gesundheit ist es notwendig, in Deutschland regelmäßige Studien zur Verbreitung von CA-MRSA durchzuführen. Medizinisches Personal muss über Krankheitsbilder, Diagnostik, Therapie und Prävention geschult sein. Infizierte und Träger sollten behandelt und der Trägerstatus saniert werden. Ziel ist es, die Verbreitung von CA-MRSA bestmöglich zu kontrollieren.
Literatur
-
1
Lowy F D.
Staphylococcus aureus infections.
N Engl J Med.
1998;
339
520-532
-
2
Deurenberg R H, Nieuwenhuis R F, Driessen C. et al .
The prevalence of the Staphylococcus aureus tst gene among community- and hospital-acquired strains and isolates from Wegener’s Granulomatosis patients.
FEMS Microbiol Lett.
2005;
245
185-189
-
3
Diep B A, Gill S R, Chang R F. et al .
Complete genome sequence of USA 300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus.
Lancet.
2006;
367
731-739
-
4
Monecke S, Berger-Bachi B, Coombs G.
Comparative genomics and DNA array-based genotyping of pandemic Staphylococcus aureus strains encoding Panton-Valentine leukocidin.
Clin Microbiol Infect.
2007;
13
236-249
-
5
Robinson D A, Enright M C.
Multilocus sequence typing and the evolution of methicillin-resistant Staphylococcus aureus.
Clin Microbiol Infect.
2004;
10
92-97
-
6
Tenover F C, McDougal L K, Goering R V. et al .
Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States.
J Clin Microbiol.
2006;
44
108-118
-
7
Chambers H F.
Community-associated MRSA-resistance and virulence converge.
N Engl J Med.
2005;
352
1485-1487
-
8
Ellis M W, Hospenthal D R, Dooley D P, Gray P J, Murray C K.
Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers.
Clin Infect Dis.
2004;
39
971-979
-
9
Seybold U, Talati N J, Kizilbash Q, Shah M, Blumberg H M, Franco-Paredes C.
Hematogenous Osteomyelitis Mimicking Osteosarcoma due to Community Associated Methicillin-Resistant Staphylococcus aureus.
Infection.
2007;
35
190-193
-
10
Mitchell P D, Hunt D M, Lyall H, Nolan M, Tudor-Williams G.
Panton-Valentine leukocidin-secreting Staphylococcus aureus causing severe musculoskeletal sepsis in children: A NEW THREAT.
J Bone Joint Surg Br.
2007;
89
1239-1242
-
11
DeWitt C A, Bishop A B, Buescher L S, Stone S P.
Hyperimmunoglobulin E syndrome: two cases and a review of the literature.
J Am Acad Dermatol.
2006;
54
855-865
-
12
Kars M, van Dijk H, Salimans M M, Bartelink A K. et al .
Association of furunculosis and familial deficiency of mannose-binding lectin.
Eur J Clin Invest.
2005;
35
531-534
-
13
Friedman N D, Peterson N B, Sumner W T, Alexander B D.
Spontaneous dermal abscesses and ulcers as a result of Serratia marcescens.
J Am Acad Dermatol.
2003;
49
193-194
-
14
Silvestre Salvador J F, Betlloch M I, Alfonso R, Ramon R L, Morell A M, Navas J.
Disseminated skin infection due to Mycobacterium fortuitum in an immunocompetent patient.
J Eur Acad Dermatol Venereol.
1998;
11
158-161
-
15
Ribeiro A, Dias C, Silva-Carvalho M C. et al .
First report of infection with community-acquired methicillin-resistant Staphylococcus aureus in South America.
J Clin Microbiol.
2005;
43
1985-1988
-
16
Tang C T, Nguyen D T, Ngo T H. et al .
An outbreak of severe infections with community-acquired MRSA carrying the Panton-Valentine leukocidin following vaccination.
PLoS ONE.
2007;
2
e822
-
17
Gonzalez B E, Hulten K G, Dishop M K. et al .
Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection.
Clin Infect Dis.
2005;
41
583-590
-
18
Gillet , Y , B I ssartel, P V anhems. et al .
Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients.
Lancet.
2002;
359
753-759
-
19
Petros S, Eggers B, Heuer M. et al .
Severe community acquired pneumonia due to Staphylococcus aureus.
Intensive Care Med.
1998;
24
189
-
20
Quadri A M, Hock Y L.
Pulmonary pathology of Panton-Valentine leukocidin gene carrying methicillin- resistant Staphylococcus aureus pneumonia.
Histopathology.
2007;
51
712-713
-
21
Adem P V, Montgomery C P, Husain A N. et al .
Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children.
N Engl J Med.
2005;
353
1245-1251
-
22 Bagnulo H, Pedreira W, Soca A, Galiana A, Uruguayan C A. MRSA Study Group .Pulmonary involvement during an outbreak of community-acquired methicillin-resistant Staphlyococcus aureus infections 2006. International Congress of Infectious Disease Lisbon; 2006
-
23
Hsu L, Koh T, Anantham D. et al .
Panton-Valentine Leukocidin-positive Staphylococcus aureus, Singapore.
Emerg Infect Dis.
2004;
10
1509-1510
-
24
Kravitz G R, Dries D J, Peterson M L, Schlievert P M.
Purpura fulminans due to Staphylococcus aureus.
Clin Infect Dis.
2005;
40
941-947
-
25
Miller L G, Perdreau-Remington F, Rieg G. et al .
Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles.
N Engl J Med.
2005;
352
1445-1453
-
26 Reyes M T, Beenhouwer D O, Rocha M A, Barack B, Drasin T, Schwartzmann W A. Serious pvl+ MRSA pulmonary infections with bacteremia and nodular infiltrates. 2006. International Congress of Infectious Disease Lisbon; 2006
-
27
Rutar T, Chambers H F, Crawford J B. et al .
Ophthalmic manifestations of infections caused by the USA 300 clone of community-associated methicillin-resistant Staphylococcus aureus.
Ophthalmology.
2006;
113
1455-1462
-
28
Okuma K, Iwakawa K, Turnidge J D. et al .
Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community.
J Clin Microbiol.
2002;
40
4289-4294
-
29
Kaneko J, Kamio Y.
Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes.
Biosci Biotechnol Biochem.
2004;
68
981-1003
-
30
Panton P N, Valentine F CO.
Staphylococcal toxin.
Lancet.
1932;
222
506-508
-
31
Wang R, Braughton K R, Kretschmer D. et al .
Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA.
Nat Med.
2007;
13
1510-1514
-
32
Lina G, Piemont Y, Godail-Gamot F. et al .
Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.
Clin Infect Dis.
1999;
29
1128-1132
-
33
Boyle-Vavra S, Daum R S.
Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin.
Lab Invest.
2007;
87
3-9
-
34
Labandeira-Rey M, Couzon F, Boisset S. et al .
Staphylococcus aureus Panton Valentine Leukocidin Causes Necrotizing Pneumonia.
Science.
2007;
315
1130-1133
-
35
Baba T, Takeuchi F, Kuroda M. et al .
Genome and virulence determinants of high virulence community-acquired MRSA.
Lancet.
2002;
359
1819-1827
-
36
Enright M C, Robinson D A, Randle G, Feil E J, Grundmann H, Spratt B G.
The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA).
Proc Natl Acad Sci USA.
2002;
99
7687-7692
-
37
Tiwari H K, Sen M R.
Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India.
BMC Infect Dis.
2006;
6
156
-
38
Faden H, Ferguson S.
Community-acquired methicillin-resistant Staphylococcus aureus and intrafamily spread of pustular disease.
Pediatr Infect Dis J.
2001;
20
554-555
-
39
Huijsdens X W, Santen-Verheuvel M G, Spalburg E. et al .
Multiple cases of familial transmission of community-acquired methicillin-resistant Staphylococcus aureus.
J Clin Microbiol.
2006;
44
2994-2996
-
40
Nordmann P, Naas T.
Transmission of methicillin-resistant Staphylococcus aureus to a microbiologist.
N Engl J Med.
2005;
352
1489-1490
-
41
Chalumeau M, Bidet P, Lina G. et al .
Transmission of Panton-Valentine leukocidin-producing Staphylococcus aureus to a physician during resuscitation of a child.
Clin Infect Dis.
2005;
41
e29-e30
-
42
Linde H, Wagenlehner F, Strommenger B. et al .
Healthcare-associated outbreaks and community-acquired infections due to MRSA carrying the Panton-Valentine leucocidin gene in southeastern Germany.
Eur J Clin Microbiol Infect Dis.
2005;
24
419-422
-
43
Centers for Disease Control .
Methicillin-resistant Staphylococcus aureus infections in correctional facilities - Georgia, California and Texas, 2001 - 2003.
MMWR.
2004;
52
992-996
-
44
Kazakova S V, Hageman J C, Matava M. et al .
A clone of methicillin-resistant Staphylococcus aureus among professional football players.
N Engl J Med.
2005;
352
468-475
-
45
Nguyen D B, Mascola L, Bancroft E.
Recurring methicillin-resistant Staphylococcus aureus infections in a football team.
Emerg Infect Dis.
2005;
11
526-532
-
46
Centers for Disease Control. .
Methicillin-resistant Staphylococcus aureus infections among competitive sports participants - Colorado, Indiana, Pennsylvania and Los Angeles County, 2000 - 2003.
MMWR.
2004;
52
793-795
-
47
Huijsdens X W, van Lier A MC, van Kregten E. et al .
Methicillin-resistant Staphylococcus aureus in Dutch Soccer Team.
Emerg Infect Dis.
2006;
12
1584-1586
-
48
Begier E M, Frenette K, Barrett N L. et al .
A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns.
Clin Infect Dis.
2004;
39
1446-1453
-
49
Fergie J E, Purcell K.
Community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children.
Pediatr Infect Dis J.
2001;
20
860-863
-
50
Cuny C, Kuemmerle J, Stanek C, Willey B, Strommenger B, Witte W.
Emergence of MRSA infections in horses in a veterinary hospital: strain characterisation and comparison with MRSA from humans.
Euro Surveill.
2006;
11
44-47
-
51
van Loo I HM, Diederen B MW, Savelkoul P HM. et al .
Methicillin-Resistant Staphylococcus aureus in Meat Products, the Netherlands.
Emerg Infect Dis.
2007;
13
1753-1755
-
52
Said-Salim B, Mathema B, Kreiswirth B N.
Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen.
Infect Control Hosp Epidemiol.
2003;
24
451-455
-
53
Smith J M, Cook G M.
A decade of community MRSA in New Zealand.
Epidemiol Infect.
2005;
133
899-904
-
54
Maier J, Melzl H, Reischl U.
Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus in Germany associated with travel or foreign family origin.
Eur J Clin Microbiol Infect Dis.
2005;
24
637-639
-
55
Moran G J, Krishnadasan A, Gorwitz R J. et al .
Methicillin-resistant S. aureus infections among patients in the emergency department.
N Engl J Med.
2006;
355
666-674
-
56
McCaig L F, McDonald L C, Mandal S, Jernigan D B.
Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care.
Emerg Infect Dis.
2006;
12
1715-1723
-
57
Ma X X, Ito T, Chongtrakool P, Hiramatsu K.
Predominance of clones carrying Panton-Valentine leukocidin genes among methicillin-resistant Staphylococcus aureus strains isolated in Japanese hospitals from 1979 to 1985.
J Clin Microbiol.
2006;
44
4515-4527
-
58
Turnidge J D, Bell J M.
Methicillin-resistant Staphylococcal aureus evolution in Australia over 35 years.
MicrobDrug Resist.
2000;
6
223-229
-
59
Chini V, Petinaki E, Foka A, Paratiras S, Dimitracopoulos G, Spiliopoulou I.
Spread of Staphylococcus aureus clinical isolates carrying Panton-Valentine leukocidin genes during a 3-year period in Greece.
Clin Microbiol Infect.
2006;
12
29-34
-
60
Lo W T, Lin W J, Tseng M H, Lu J J, Chu M L, Wang C C.
Nasal carriage of a single clone of community-acquired methicillin-resistant Staphylococcus aureus among kindergarten attendees in northern Taiwan.
BMC Infect Dis.
2007;
7
51
-
61
Salgado C D, Farr B M, Calfee D P.
Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors.
Clin Infect Dis.
2003;
36
131-139
-
62
Witte W, Strommenger B, Cuny C, Heuck D, Nuebel U.
Methicillin-resistant Staphylococcus aureus containing the Panton-Valentine leucocidin gene in Germany in 2005 and 2006.
J Antimicrob Chemother.
2007;
66
1258-1263
-
63
Kluytmans-Vandenbergh M F, Kluytmans J A.
Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives.
Clin Microbiol Infect.
2006;
12 Suppl 1
9-15
-
64
Furuya E Y, Cook H A, Lee M H. et al .
Community-associated methicillin-resistant Staphylococcus aureus prevalence: how common is it? A methodological comparison of prevalence ascertainment.
Am J Infect Control.
2007;
35
359-366
-
65
Grayson M L.
The treatment triangle for staphylococcal infections.
N Engl J Med.
2006;
355
724-727
-
66
Zetola N, Francis J S, Nuermberger E L, Bishai W R.
Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat.
Lancet Infect Dis.
2005;
5
275-286
-
67
Witte W.
cMRSA: Heteroresistenztyp erfordert besondere diagnostische Aufmerksamkeit.
Epidemiologisches Bulletin.
2005;
50
466-467
-
68
Obed A, Schnitzbauer A A, Bein T, Lehn N, Linde H J, Schlitt H J.
Fatal Pneumonia Caused by Panton-Valentine Leucocidine-Positive Methicillin-Resistant Staphylococcus aureus (PVL-MRSA) Transmitted from a Healthy Donor in Living-Donor Liver Transplantation.
Transplantation.
2006;
81
121-124
-
69
Miller L G, Quan C, Shay A. et al .
A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection.
Clin Infect Dis.
2007;
44
483-492
-
70
Davis S L, Perri M B, Donabedian S M. et al .
Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection.
J Clin Microbiol.
2007;
45
1705-1711
-
71
Bernardo K, Pakulat N, Fleer S. et al .
Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression.
Antimicrob Agents Chemother.
2004;
48
546-444
-
72
Ohlsen K, Ziebuhr W, Koller K P, Hell W, Wichelhaus T A, Hacker J.
Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates.
Antimicrob Agents Chemother.
1998;
42
2817-2823
-
73
Micek S T, Dunne M, Kollef M H.
Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production.
Chest.
2005;
128
2732-2738
-
74
Morgan M S.
Diagnosis and treatment of Panton-Valentine leukocidin (PVL)-associated staphylococcal pneumonia.
Int J Antimicrob Agents.
2007;
30
289-296
-
75
Gauduchon V, Cozon G, Vandenesch F. et al .
Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro.
J Infect Dis.
2004;
189
346-353
-
76
Fatkenheuer G, Preuss M, Salzberger B. et al .
Long-term outcome and quality of care of patients with Staphylococcus aureus bacteremia.
Eur J Clin Microbiol Infect Dis.
2004;
23
157-162
-
77
Ringberg H, Thoren A, Lilja B.
Metastatic complications of Staphylococcus aureus septicemia. To seek is to find.
Infection.
2000;
28
132-136
-
78 Gorwitz R, Jernigan D B, Jernigan J A. Minimizing the impact of Methicillin-resistant Staphylococcus aureus in the community [conference summary]. Emerg Infect Dis June/2006 http://Available from http://www.gov/ncidod/EID/vol12no06/06-0292.htm
-
79
Wagenlehner F M, Naber K G, Bambl E.
Management of a large healthcare-associated outbreak of Panton-Valentine leucocidin-positive meticillin-resistant Staphylococcus aureus in Germany.
J Hosp Infect.
2007;
67
114-120
-
80
Wiese-Posselt M, Heuck D, Draeger A. et al .
Successful termination of a furunculosis outbreak due to lukS-lukF-positive, methicillin-susceptible Staphylococcus aureus in a German village by stringent decolonization, 2002 - 2005.
Clin Infect Dis.
2007;
44
e88-e95
-
81
Roesch A, Linde H J, Landthaler M, Vogt T.
Elimination of a community-acquired methicillin-resistant Staphylococcus aureus infection in a nurse with atopic dermatitis.
Arch Dermatol.
2005;
141
1520-1522
-
82
Witte W, Wiese-Posselt M, Jappe U.
Community-based MRSA A new challenge for dermatology.
Hautarzt.
2005;
56
731-738
-
83
Levy R, Shriker O, Porath A, Riesenberg K, Schlaeffer F.
Vitamin C for the treatment of recurrent furunculosis in patients with imparied neutrophil functions.
J Infect Dis.
1996;
173
1502-1505
-
84
Raz R, Miron D, Colodner R, Staler Z, Samara Z, Keness Y.
A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection.
Arch Intern Med.
1996;
156
1109-1112
-
85
Klempner M S, Styrt B.
Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy.
JAMA.
1988;
260
2682-2685
-
86
Nahmias A J, Lepper M H, Hurst V, Mudd S.
Epidemiology and treatment of chronic staphylococcal infections in the household.
Am J Public Health.
1962;
52
1828-1843
-
87
Massey R C, Horsburgh M J, Lina G, Hook M, Recker M.
The evolution and maintenance of virulence in Staphylococcus aureus: a role for host-to-host transmission.
Nat Rev Microbiol.
2006;
4
953-958
-
88
Tietz A, Frei R, Widmer A F.
Transatlantic spread of the USA 300 clone of MRSA.
N Engl J Med.
2005;
353
532-533
Priv.-Doz. Dr. med. Hans-Jörg Linde
Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg
Franz-Josef-Strauß-Allee 11
93043 Regensburg
Phone: 0941/9446414
Fax: 0941/9446402
Email: Hans-Joerg.Linde@klinik.uni-regensburg.de
